Pentoxifylline Reduces Pro-inflammatory And Increases Anti-inflammatory Activity In Patients With Coronary Artery Disease-a Randomized Placebo-controlled Study

dc.creatorFernandes J.L.
dc.creatorde Oliveira R.T.D.
dc.creatorMamoni R.L.
dc.creatorCoelho O.R.
dc.creatorNicolau J.C.
dc.creatorBlotta M.H.S.L.
dc.creatorSerrano Jr. C.V.
dc.date2008
dc.date2015-06-30T19:14:55Z
dc.date2015-11-26T14:40:27Z
dc.date2015-06-30T19:14:55Z
dc.date2015-11-26T14:40:27Z
dc.date.accessioned2018-03-28T21:46:42Z
dc.date.available2018-03-28T21:46:42Z
dc.identifier
dc.identifierAtherosclerosis. , v. 196, n. 1, p. 434 - 442, 2008.
dc.identifier219150
dc.identifier10.1016/j.atherosclerosis.2006.11.032
dc.identifierhttp://www.scopus.com/inward/record.url?eid=2-s2.0-38049079202&partnerID=40&md5=08a83e42cc3f8333540fb06cdc5aef6c
dc.identifierhttp://www.repositorio.unicamp.br/handle/REPOSIP/105408
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/105408
dc.identifier2-s2.0-38049079202
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1250404
dc.descriptionThe balance between different immunological stimuli is essential in the progression and stabilization of atherosclerotic plaques. Immune regulation has been suggested as potential target for the treatment of atherosclerotic disease. We sought to determine whether treatment with pentoxifylline, a phosphodiesterase inhibitor with immunomodulating properties, could reduce the pro-inflammatory response observed in patients with acute coronary syndromes (ACS) and increase anti-inflammatory activity. In a double-blind, prospective, placebo-controlled study, 64 patients with ACS were randomized to receive pentoxifylline 400 mg TID or placebo for 6 months. Analysis of the pro-inflammatory markers, C-reactive protein (CRP), interleukin (IL)-6, IL-12, interferon-gamma and tumor necrosis factor (TNF)-α and the anti-inflammatory cytokines, transforming growth factor (TGF)-β1 and IL-10 were done at baseline, 1 and 6 months. Pentoxifylline treatment significantly reduced the adjusted levels of CRP and TNF-α compared to placebo after 6 months (P = 0.04 and P < 0.01, respectively). IL-12 increase was significantly less pronounced with pentoxifylline (P = 0.04). The levels of the anti-inflammatory cytokine, IL-10, also declined significantly less in the pentoxifylline group compared to placebo (P < 0.01) with a trend towards a higher increase of TGF-β1 in the former group (P = 0.16). Pentoxifylline reduces pro-inflammatory and increases anti-inflammatory response in patients with ACS and may have beneficial clinical effects on cardiovascular events. © 2006 Elsevier Ireland Ltd. All rights reserved.
dc.description196
dc.description1
dc.description434
dc.description442
dc.descriptionHansson, G.K., Inflammation, atherosclerosis, and coronary artery disease (2005) N Engl J Med, 352, pp. 1685-1695
dc.descriptionFrostegard, J., Ulfgren, A.K., Nyberg, P., Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines (1999) Atherosclerosis, 145, pp. 33-43
dc.descriptionZhou, X., Paulsson, G., Stemme, S., Hypercholesterolemia is associated with a T helper (Th) 1/Th2 switch of the autoimmune response in atherosclerotic apo E-knockout mice (1998) J Clin Invest, 101, pp. 1717-1725
dc.descriptionUyemura, K., Demer, L.L., Castle, S.C., Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis (1996) J Clin Invest, 97, pp. 2130-2138
dc.descriptionFernandes, J.L., Mamoni, R.L., Orford, J.L., Increased Th1 activity in patients with coronary artery disease (2004) Cytokine, 26, pp. 131-137
dc.descriptionLiuzzo, G., Vallejo, A.N., Kopecky, S.L., Molecular fingerprint of interferon-gamma signaling in unstable angina (2001) Circulation, 103, pp. 1509-1514
dc.descriptionLiuzzo, G., Biasucci, L.M., Gallimore, J.R., The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina (1994) N Engl J Med, 331, pp. 417-424
dc.descriptionBiasucci, L.M., Vitelli, A., Liuzzo, G., Elevated levels of interleukin-6 in unstable angina (1996) Circulation, 94, pp. 874-877
dc.descriptionPinderski Oslund, L.J., Hedrick, C.C., Olvera, T., Interleukin-10 blocks atherosclerotic events in vitro and in vivo (1999) Arterioscler Thromb Vasc Biol, 19, pp. 2847-2853
dc.descriptionGrainger, D.J., Transforming growth factor beta and atherosclerosis: so far, so good for the protective cytokine hypothesis (2004) Arterioscler Thromb Vasc Biol, 24, pp. 399-404
dc.descriptionCipollone, F., Fazia, M., Mincione, G., Increased expression of transforming growth factor-beta1 as a stabilizing factor in human atherosclerotic plaques (2004) Stroke, 35, pp. 2253-2257
dc.descriptionMallat, Z., Tedgui, A., The role of transforming growth factor beta in atherosclerosis: novel insights and future perspectives (2002) Curr Opin Lipidol, 13, pp. 523-529
dc.descriptionLutgens, E., Cleutjens, K.B., Heeneman, S., Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype (2000) Proc Natl Acad Sci USA, 97, pp. 7464-7469
dc.descriptionZhao, L., Cuff, C.A., Moss, E., Selective interleukin-12 synthesis defect in 12/15-lipoxygenase-deficient macrophages associated with reduced atherosclerosis in a mouse model of familial hypercholesterolemia (2002) J Biol Chem, 277, pp. 35350-35356
dc.descriptionLaurat, E., Poirier, B., Tupin, E., In vivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice (2001) Circulation, 104, pp. 197-202
dc.descriptionRamani, M., Khechai, F., Ollivier, V., Interleukin-10 and pentoxifylline inhibit C-reactive protein-induced tissue factor gene expression in peripheral human blood monocytes (1994) FEBS Lett, 356, pp. 86-88
dc.descriptionD'Hellencourt, C.L., Diaw, L., Cornillet, P., Differential regulation of TNF alpha, IL-1 beta, IL-6, IL-8, TNF beta, and IL-10 by pentoxifylline (1996) Int J Immunopharmacol, 18, pp. 739-748
dc.descriptionWard, A., Clissold, S.P., Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy (1987) Drugs, 34, pp. 50-97
dc.descriptionSliwa, K., Woodiwiss, A., Kone, V.N., Therapy of ischemic cardiomyopathy with the immunomodulating agent pentoxifylline: results of a randomized study (2004) Circulation, 109, pp. 750-755
dc.descriptionRidker, P.M., Cannon, C.P., Morrow, D., C-reactive protein levels and outcomes after statin therapy (2005) N Engl J Med, 352, pp. 20-28
dc.descriptionBhatt, D.L., Topol, E.J., Need to test the arterial inflammation hypothesis (2002) Circulation, 106, pp. 136-140
dc.descriptionBelloc, F., Jaloustre, C., Dumain, P., Effect of pentoxifylline on apoptosis of cultured cells (1995) J Cardiovasc Pharmacol, 25 (SUPPL. 2), pp. S71-S74
dc.descriptionNeuner, P., Klosner, G., Schauer, E., Pentoxifylline in vivo down-regulates the release of IL-1 beta, IL-6, IL-8 and tumour necrosis factor-alpha by human peripheral blood mononuclear cells (1994) Immunology, 83, pp. 262-267
dc.descriptionBoldt, J., Brosch, C., Lehmann, A., Prophylactic use of pentoxifylline on inflammation in elderly cardiac surgery patients (2001) Ann Thorac Surg, 71, pp. 1524-1529
dc.descriptionBoldt, J., Brosch, C., Piper, S.N., Influence of prophylactic use of pentoxifylline on postoperative organ function in elderly cardiac surgery patients (2001) Crit Care Med, 29, pp. 952-958
dc.descriptionBenagiano, M., Azzurri, A., Ciervo, A., T helper type 1 lymphocytes drive inflammation in human atherosclerotic lesions (2003) Proc Natl Acad Sci USA, 100, pp. 6658-6663
dc.descriptionGupta, S., Pablo, A.M., Jiang, X., IFN-gamma potentiates atherosclerosis in ApoE knock-out mice (1997) J Clin Invest, 99, pp. 2752-2761
dc.descriptionTerkeltaub, R.A., IL-10: an "immunologic scalpel" for atherosclerosis? (1999) Arterioscler Thromb Vasc Biol, 19, pp. 2823-2825
dc.descriptionHeeschen, C., Dimmeler, S., Hamm, C.W., Serum level of the antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes (2003) Circulation, 107, pp. 2109-2114
dc.descriptionBogaty, P., Brophy, J.M., Noel, M., Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomized placebo-controlled study (2004) Circulation, 110, pp. 934-939
dc.languageen
dc.publisher
dc.relationAtherosclerosis
dc.rightsfechado
dc.sourceScopus
dc.titlePentoxifylline Reduces Pro-inflammatory And Increases Anti-inflammatory Activity In Patients With Coronary Artery Disease-a Randomized Placebo-controlled Study
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución